To observe the clinical efficacy and safety of evolocumab injection combined with pitavastatin calcium tablets in the treatment of patients with acute coronary syndrome after percutaneous coronary intervention (PCI).

According to cohort method, the patients with acute coronary syndrome after PCI were divided into control group and treatment group. Two groups were treated with routine treatment (anti-platelet, anti-coagulation, reducing myocardial oxygen consumption, improving myocardial ischemia). On the routine treatment, control group was treated with pitavastatin calcium 2 mg per time, once a day, orally before bedtime. On the basis of control group, treatment group was given evolocumab 140 mg per time, once every 2 weeks, subcutaneous injection. Two groups were treated for 6 months. The clinical efficay, blood lipid, myocardial injury indexes, serum levels of amyloid A1 (SAA1) and Gla-rich protein (GRP), major adverse cardiovascular events (MACEs) and safety were compared between two groups.

Fifty-two patients were enrolled in the treatment group and 58 patients were enrolled in the control group. After treatment, the total effective rates of treatment and control groups were 94.23% (49 cases/52 cases) and 75.86% (44 cases/58 cases), and the difference was statistically significant (P<0.05). After treatment, the total cholesterol levels of treatment and control groups were (1.17±0.22) and (1.35±0.25) mmol·L^-1, triglyceride levels were (2.63±0.76) and (3.89±0.92) mmol·L^-1, high-density lipoprotein cholesterol levels were (1.41±0.30) and (1.26±0.28) mmol·L^-1, low-density lipoprotein cholesterol levels were (1.23±0.46) and (1.58±0.55) mmol·L^-1, cardiac troponin I levels were (0.03±0.01) and (0.05±0.02) ng·mL^-1, creatine kinase isoenzyme levels were (12.35±2.38) and (14.23±2.89) U·L^-1, SAA1 levels were (213.92±41.58) and (274.18±43.36) μg·mL^-1, GRP levels were (21.32±3.50) and (19.35±3.27) ng·mL^-1, incidences of MACEs were 9.62% and 24.14%, the differences were statistically significant between two groups (all P<0.05). The adverse drug reactions of two groups were fatigue, pruritus, abdominal pain and elevated aminotransferase. There was no significant difference in total incidences of adverse drug reactions between treatment group and control group (11.54% vs 13.79%, P>0.05).

Evolocumab injection combined with pitavastatin calcium tablets has a definitive clinical efficacy in the treatment of patients with acute coronary syndrome after PCI, which can effectively reduce the blood lipid levels, the incidence of MACEs and myocardial injury, regulate the serum levels of SAA1 and GRP, without increasing the incidence of adverse drug reactions.